Related Experiment Videos
Phase II trial of N-methylformamide in patients with metastatic melanoma
O Eton1, D F Bajorin, E S Casper
1Department of Medicine, Memorial-Sloan Kettering Cancer Center, New York.
Abstract:
Sixteen patients with metastatic melanoma were treated with N-methylformamide (NMF), a polar-planar compound with in vitro cytotoxic and differentiating properties. Sixteen patients were evaluable for toxicity and 14 for response. The initial four patients received an intravenous bolus of NMF 800 mg/m2 daily for 5 consecutive days every 28 days. Because of excessive gastrointestinal toxicity, the dose was reduced to 700 mg/m2/day for the subsequent 12 patients. Two patients had immediate adverse effects from NMF; one had a grand mal seizure and the other developed severe abdominal pain. Nausea, vomiting and abdominal pain were dose-limiting. Transient elevation of liver function tests occurred in all patients. Myelosuppression was not observed. There were no objective responses among 14 evaluable patients (95% confidence limits 0-20%). One patient with pulmonary metastases had a minor response lasting 13 months. Median time to progression of disease was one month. NMF in these doses and schedule lacks clinical efficacy in the treatment of metastatic melanoma.
Insights
N-methylformamide (NMF) showed no significant efficacy in treating metastatic melanoma patients. The drug caused dose-limiting gastrointestinal toxicity and transient liver function abnormalities, indicating it is not a viable treatment option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic melanoma is an advanced form of skin cancer with limited treatment options.
- N-methylformamide (NMF) is a polar-planar compound investigated for its cytotoxic and differentiating properties against cancer cells.
Purpose of the Study:
- To evaluate the clinical efficacy and toxicity of N-methylformamide (NMF) in patients with metastatic melanoma.
Main Methods:
- A phase II clinical trial was conducted involving 16 patients with metastatic melanoma.
- Patients received NMF intravenously at doses of 800 mg/m2 or 700 mg/m2 daily for 5 consecutive days every 28 days.
- Toxicity and objective response rates were assessed in evaluable patients.
Main Results:
- NMF treatment resulted in dose-limiting gastrointestinal toxicity, including nausea, vomiting, and abdominal pain.
- Transient elevations in liver function tests were observed in all patients; no myelosuppression occurred.
- No objective responses were observed in 14 evaluable patients, with one patient showing a minor response.
Conclusions:
- N-methylformamide (NMF) demonstrated a lack of clinical efficacy in treating metastatic melanoma at the tested doses and schedule.
- The observed gastrointestinal toxicity limits its therapeutic potential in this patient population.